Organometallic Ligands

Flavoxate is a muscarinic antagonist and spasmolytic drug that is used for the relief of conditions associatied with a lack of muscle control in the bladder such as urine urgency. This drug acts as a direct antagonist on acetylcholine receptors. This action reduces the tonus of smooth muscles in the bladder. Flavoxate is part of our Bio-X ™ Range. These products are aimed at life science researchers who need high quality ready-to-use products for assay development, screening or other R&D work. With a solubility datasheet and convenient vials, all of our Bio-X ™ products are in stock across our global warehouses for rapid delivery and ease of use.

Induces Kruppel like factor 4 (KLF4) and reduces the expression of MYC.  Anti-tumor activity of APTO 253 has been demonstrated in AML and haematological malignancies. Inducing KLP4 expression in ovarian cancer cells using APT0 253 sensitises cells to cisplatin  and paclitaxel. BRCA1/2-deficient cancer cells are hypersensitive to APTO 253, which mediates its action by causing DNA damage.

Please enquire for more information about MDK34597 including the price, delivery time and more detailed product information at the technical inquiry form on this page

GSK334429 hydrochloride is a selective corticotropin-releasing factor 1 (CRF1) receptor antagonist, which is a synthetic compound developed by GlaxoSmithKline. As a small-molecule antagonist, it acts by binding to the CRF1 receptor, thereby inhibiting the action of corticotropin-releasing factor (CRF). This interruption in CRF signaling is significant as CRF is a key regulator in the body’s response to stress, influencing both endocrine and behavioral reactions. GSK334429 hydrochloride has been extensively studied for its potential therapeutic applications, primarily in the management of stress-related disorders such as anxiety, depression, and irritable bowel syndrome (IBS). By blocking the CRF1 receptors, GSK334429 is hypothesized to attenuate the overactive stress responses that characterize these conditions. The compound's ability to selectively target CRF1 receptors without significant cross-reactivity with other receptor types is crucial for minimizing side effects and enhancing therapeutic efficacy. In research settings, this compound is utilized to further understand the pathophysiology of stress-related conditions and to evaluate the potential of CRF1 receptor antagonism as a therapeutic strategy. The development of GSK334429 hydrochloride marks a significant step in exploring novel treatments targeting the CRF signaling pathway.

H1-receptor antagonist

Inhibitor of sodium-glucose cotransporter SGLT2

Inhibitor of O-GlcNAcase and N-acetylhexosaminidases

ISA-2011B is a corrosion inhibitor, which is a synthetic compound designed to minimize or prevent the degradation of metals caused by environmental factors. It is derived from a specialized chemical synthesis process, ensuring high purity and efficacy in various industrial applications. The mode of action involves forming a protective film on the surface of metal substrates, thereby blocking corrosive agents such as moisture, oxygen, and salts from making contact with the metal surface. ISA-2011B is utilized extensively in the petroleum, chemical processing, and water treatment industries. Its application is crucial in safeguarding metal components and infrastructure in harsh environments, thus extending the operational lifespan and reliability of equipment. Researchers and engineers incorporate ISA-2011B into formulations designed for coatings, fuel additives, and as a critical component in maintenance protocols for pipelines and storage tanks. Understanding its behavior and interaction with different metals allows for optimized use in preserving the integrity of valuable assets in technology-intensive settings.

Calcitriol is a steroid hormone, vitamin D metabolite and agonist of vitamin D receptor (VDR), also known as calcitriol receptor. It regulates absorption of calcium from intestine, resorption of bone calcium and calcium excretion via kidneys. This compound also controls cell cycle, promotes cell differentiation, triggers apoptosis and acts as anti-inflammatory factor within the tumor microenvironment. It has anti-proliferative effects in malignant epithelial cells and in tumour-derived endothelial cells (TDEC). Also, it is a potent inhibitor of retinal neoangiogenesis in vitro.

Sphingosine-1-phosphate receptor modulator

2-[[5-[4-(Dimethylsulfamoyl)phenyl]-8-methyl-2-oxo-1,6,7,9-tetrahydropyrrolo[3,2-H]isoquinolin-3-ylidene]amino]oxy-4-hydroxybutanoic acid is a synthetic isoquinoline derivative, often investigated in the field of medicinal chemistry and cancer pharmacology. This compound is typically synthesized through complex organic reactions involving the modification of isoquinoline skeletons, commonly used as scaffolds for designing biologically active molecules. The compound exerts its activity by inhibiting specific enzymes or receptors involved in cancer cell proliferation and survival. Typically, its mode of action involves the disruption of cellular signaling pathways or interference with DNA replication mechanisms, thereby impairing the growth and division of malignant cells. Research has demonstrated the potential applications of this compound as a chemotherapeutic agent. It is explored primarily in preclinical studies to evaluate its efficacy in targeting various cancer types. Additionally, structure-activity relationship (SAR) studies are often conducted to optimize its pharmacokinetic and pharmacodynamic properties, aiming to increase selectivity and potency while minimizing potential side effects. Ongoing research seeks to delineate its therapeutic index and further understand its role in combination therapies.

Synthetic estradiol derivative

MEDICA16: GPR40 agonist, GPR120 partial agonist, ATP-citrate lyase inhibitor, lowers TG, boosts insulin sensitivity in muscle.

Inhibitor of ALK1, ALK2, ALK3 and ALK6 kinases and bone morphogenetic protein (BMP) pathway. LDN 1931189 is a dorsomorphin derivative that inhibits BMP-mediated activation of Smad, Akt and p38 signalling. LDN 193189 promotes differentiation of human pluripotent cells into PAX6+ anterior neural ectoderm. In combination with basic fibroblast growth factor (FGF2), LDN 193189 promotes differentiation of mouse pluripotent stem cells into inner ear sensory epithelium.

DT2216 is a small-molecule anticancer compound, which is a product of rational drug design originating from advanced chemical synthesis techniques. The primary mode of action of DT2216 involves selectively targeting and disrupting BCL-XL interactions with pro-apoptotic proteins. By specifically degrading BCL-XL, DT2216 enhances the induction of apoptosis in cancer cells, thereby addressing the challenge of resistance associated with conventional therapies. This compound serves particular utility in the research and treatment of hematological malignancies and solid tumors where BCL-XL has been implicated in survival pathways. Investigations into DT2216 have demonstrated efficacy in tumor reduction in preclinical models, with a reduced impact on platelet levels compared to traditional BCL-XL inhibitors. This specificity minimizes adverse effects, thus offering a significant advantage over other therapeutic strategies. Research applications of DT2216 span mechanistic studies of apoptosis and the exploration of combination treatment regimens, thereby contributing to the broader understanding of cell death pathways in oncology. The development of DT2216 underscores the potential of targeted protein degradation as an innovative approach in cancer therapy, offering a promising avenue for future clinical applications.

AFN-1252 is a synthetic antibiotic compound, which is derived from a biosynthetic origin tailored for specificity towards bacterial targets. Its mode of action involves the selective inhibition of enoyl-ACP reductase, an enzyme integral to the bacterial fatty acid synthesis pathway. By targeting this enzyme, AFN-1252 effectively disrupts the production of essential fatty acids, leading to the attenuation of bacterial growth and proliferation. This compound is primarily applied in the treatment of Gram-positive bacterial infections, with an emphasis on resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA). The specificity of AFN-1252 for bacterial cells minimizes off-target effects on human cells, rendering it a promising agent in clinical settings where resistance to conventional antibiotics poses significant treatment challenges. Researchers have focused on evaluating its pharmacokinetics and therapeutic efficacy in preclinical and clinical trials, making it a significant subject in the study of novel antibacterial agents.

Aclidinium is a long-acting bronchodilator that is used to treat chronic cough and other symptoms of airway obstruction. It is also used to prevent bronchospasm in people who are at risk for developing asthma attacks. This drug binds to all 5 acetylcholine muscarinic receptor subtypes and results in bronchodilation. Aclidinium bromide is part of our Bio-X ™ Range. These products are aimed at life science researchers who need high quality ready-to-use products for assay development, screening or other R&D work. With a solubility datasheet and convenient vials, all of our Bio-X ™ products are in stock across our global warehouses for rapid delivery and ease of use.

This product is part of our Bio-X ™ Range. These products are aimed at life science researchers who need high quality ready-to-use products for assay development, screening or other R&D work. With a solubility datasheet and convenient vials, all of our Bio-X ™ products are in stock across our global warehouses for rapid delivery and ease of use.

AVN-492 is an anti-inflammatory compound, derived from specific medicinal plant sources. It operates through the modulation of inflammatory pathways, primarily by inhibiting key inflammatory mediators such as cytokines and enzymes involved in the inflammatory response. This is achieved by targeting molecular receptors and signalling pathways that are crucial in the regulation of inflammation. AVN-492 is utilized in a variety of therapeutic applications, including the management of chronic inflammatory diseases such as arthritis, cardiovascular inflammation, and certain autoimmune disorders. Its efficacy in reducing inflammatory biomarkers and alleviating symptoms has been documented in several preclinical and clinical studies. Researchers are particularly interested in its potential to attenuate oxidative stress, which often accompanies chronic inflammation. The compound’s botanical origin also suggests potential for a favorable safety profile, offering an alternative to synthetic anti-inflammatory agents that may carry significant side effects. AVN-492 is thus a subject of ongoing research, aiming to further elucidate its molecular mechanisms and extend its therapeutic applicability across a broader range of pathologies.

Please enquire for more information about ASP3026 including the price, delivery time and more detailed product information at the technical inquiry form on this page